Stock Events

Stock Events

Immuneering 

$5.51
52
+$0.17+3.28% Today

Statistics

Day High
5.59
Day Low
5.19
52W High
10.08
52W Low
1.1
Volume
152,976
Avg. Volume
1,634,640
Mkt Cap
355.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.58
-0.45
-0.31
-0.18
Expected EPS
-0.27638
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-122.07MNet Income

Analyst Ratings

$15.33Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Immuneering's focus on leveraging bioinformatics for drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biotech space with a strong emphasis on genetic and genomic analysis to develop drugs, aligning with Immuneering's approach to disease understanding.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology pioneer that competes with Immuneering in the development of novel therapeutics, particularly in the oncology and inflammation sectors.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Immuneering's interests, including cancer and inflammatory diseases.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes with Immuneering by focusing on the development of therapies for neurological and neurodegenerative diseases, a potential area of interest for Immuneering's bioinformatics-driven drug discovery.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes across a broad range of therapeutic areas, including those targeted by Immuneering's drug development efforts.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a wide range of products that compete with Immuneering's efforts in drug discovery and development, especially in the oncology space.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is known for its innovative medicines and vaccines, including cancer treatments that compete with Immuneering's focus on developing novel therapeutics using computational biology.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a competitor due to its extensive portfolio in oncology, immunology, and cardiovascular diseases, areas that Immuneering may target through its computational drug discovery platform.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company competes with Immuneering by investing heavily in bioinformatics and computational biology to accelerate drug discovery and development in areas like oncology and diabetes.

About

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Show more...
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Employees
54
Country
US
ISIN
US45254E1073

Listings

BOATS
BOATS
IMRX.BOATS
XNAS
US
IMRX

0 Comments

Share your thoughts

FAQ

What is Immuneering stock price today?▼
The current price of IMRX is $5.51 USD — it has increased by +3.28% in the past 24 hours. Watch Immuneering stock price performance more closely on the chart.
What is Immuneering stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immuneering stocks are traded under the ticker IMRX.
Is Immuneering stock price growing?▼
IMRX stock has risen by +5.56% compared to the previous week, the month change is a +10.2% rise, over the last year Immuneering has showed a +253.21% increase.
What is Immuneering market cap?▼
Today Immuneering has the market capitalization of 355.46M
When is the next Immuneering earnings date?▼
Immuneering is going to release the next earnings report on May 12, 2026.
What were Immuneering earnings last quarter?▼
IMRX earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.31 USD resulting in a +42.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immuneering revenue for the last year?▼
Immuneering revenue for the last year amounts to 0 USD.
What is Immuneering net income for the last year?▼
IMRX net income for the last year is -122.07M USD.
How many employees does Immuneering have?▼
As of April 02, 2026, the company has 54 employees.
In which sector is Immuneering located?▼
Immuneering operates in the Health Care sector.
When did Immuneering complete a stock split?▼
Immuneering has not had any recent stock splits.
Where is Immuneering headquartered?▼
Immuneering is headquartered in Cambridge, US.